

From *Modern Approaches to Clinical Trials Using SAS®*.
Full book available for purchase here.

Contents

Foreword . . . . . *vii*
About This Book . . . . . *ix*
About the Author . . . . . *xiii*
Acknowledgments . . . . . *xv*

Chapter 1 • Overview of Clinical Trials in Support of Drug Development **1**
1.1 Introduction 1
1.2 Evolution of Clinical Trials and the Emergence of Guidance Documents 4
1.3 Emergence of Group Sequential Designs in the 70s and 80s 6
1.4 Emergence of Adaptive Designs in the 90s 8
1.5 Widespread Research on Adaptive Designs Since the Turn of the 21st Century 9
1.6 Opportunities and Challenges in Designing, Conducting, and Analyzing Adaptive Trials 11
1.7 The Future of Adaptive Trials in Clinical Drug Development 13
References 15
Authors 21

Chapter 2 • Designing and Monitoring Group Sequential Clinical Trials **23**
2.1 Introduction 23
2.2 Examples of Classical Fixed-Sample Designs 26
2.3 Theories of Group Sequential Tests 30
2.4 Types of Stopping Boundaries 37
2.5 Special Issues 66
2.6 Summary 70
References 70
Authors 72

Chapter 3 • Sample Size Re-estimation **73**
3.1 Introduction 73
3.2 Blinded SSR Methods 75
3.3 Unblinded SSR Methods 77
3.4 Information-Based Design 98
3.5 Summary and Conclusions 103
References 104
Authors 106

Chapter 4 • Bayesian Survival Meta-Experimental Design Using Historical Data **107**
4.1 Introduction 107
4.2 Meta Design Setting 108
4.3 Meta-Regression Survival Models 111
4.4 Bayesian Meta-Experimental Design 113
4.5 Specification of Prior Distributions 114
4.6 Computational Algorithms 115
4.7 SAS MACRO BSMED 117
4.8 Summary 127
References 127
Authors 128
Appendix 129

Chapter 5 • Continual Reassessment Methods **133**
5.1 Dose Finding in Oncology 133
5.2 Continual Reassessment Method 133
5.3 Bayesian Model Averaging Continual Reassessment Method 138
5.4 Fractional Continual Reassessment Method 147
5.5 Time-to-Event Continual Reassessment Method 154
5.6 Summary 160
References 160
Authors 161

Chapter 6 • Classical Dose-Response Study **163**
6.1 Introduction 163
6.2 Statistical Design Considerations in a Classical Dose-Response Study 164
6.3 Considerations in the Design and Final Analysis Stages 182
6.4 Analysis Examples Using Simulated Data 182
6.5 Summary 190
References 191
Authors 192

Chapter 7 • Implementing the MCP-Mod Procedure for Dose-Response Testing and Estimation **193**
7.1 Introduction 193
7.2 Methodology 194
7.3 Considerations for MCP-Mod at the Design Stage 199
7.4 Further Considerations on MCP-Mod 200
7.5 Analysis Examples Using SAS 201
7.6 Conclusions 209
References 211
Authors 212
Appendix 213

Chapter 8 • Bayesian Dose Response **225**
8.1 Introduction and Background 225
8.2 Statistical Model for Bayesian Dose-Response 226
8.3 Analysis Examples for a Continuous Endpoint 227
8.4 Analysis Example for a Binary Endpoint 238
8.5 Summary 245
References 246
Authors 246

Chapter 9 • Overview of Adaptive Randomization **247**
9.1 Introduction 247
9.2 Simple Randomization 248
9.3 Restricted Randomization 250
9.4 Covariate-Adaptive Randomization 253
9.5 Response-Adaptive Randomization 263
9.6 Summary 270
References 271
Authors 272

Chapter 10 • Optimal Response-Adaptive Randomization Designs in Binary Outcome Clinical Trials **273**
10.1 Introduction 273
10.2 Optimal Allocation 278
10.3 Response-Adaptive Randomization for Implementing Optimal Allocation 282
10.4 Simulation of Optimal Response-Adaptive Randomization Procedures 287

10.5 Power and Sample Size for Response-Adaptive Randomization 292
10.6 Additional Considerations 295
10.7 Examples 296
10.8 Summary 299
References 300
Authors 303

Chapter 11 • Population Enrichment Designs **305**
11.1 Introduction 305
11.2 Classical Designs 308
11.3 Efficiency of Classical Enrichment Designs 314
11.4 Adaptive Enrichment Designs 322
11.5 Summary 334
References 334
Authors 338

Index **339**

From *Modern Approaches to Clinical Trials Using SAS®: Classical, Adaptive, and Bayesian Methods*, by Sandeep M. Menon and Richard C. Zink. Copyright © 2015, SAS Institute Inc., Cary, North Carolina, USA. ALL RIGHTS RESERVED.